It should be noted that Pfizer India’s parent company Pfizer has already obtained emergency use authorization in the UK and Bahrain.
According to an official source, “Pfizer India has requested permission for emergency use authorization of its Covid-19 from DGCI to import and trade.”
The application was submitted by Pfizer India on December 4 to DCGI seeking an Emergency Use Authorization (USA) for its vaccine in India.
Pfizer India has submitted the US application on Form CT-18 for the granting of permission to import and market the Covid-19 vaccine from Pfizer-BioNTech in India.
The extremely low temperature of minus 70 degrees Celsius, required to store the vaccine, poses a great challenge for delivery in a country like India.
On December 2, the UK became the first country to approve the Pfizer / BioNTech coronavirus vaccine. The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a temporary authorization for the emergency use of the coronavirus vaccine developed by Pfizer.
On Friday, Bahrain also granted permission for the two-dose vaccine made by Pfizer and its German partner BioNTech.
Recently, at an all-party meeting, Prime Minister Narendra Modi said that the Covid-19 vaccine is expected to be ready in the next few weeks, and as soon as scientists give a green signal, vaccination will begin in India. Meanwhile, India recorded 36,011 new Covid-19 infections in the past 24 hours, the Union Ministry of Health and Family Welfare said on Sunday.
Total Covid-19 cases in India reached 96,44,222, including 4,03,248 active cases and 91,00,792 recoveries. With 482 new deaths, the cumulative figure rose to 1,40,182.
.
